2013 /PRNewswire/ -- Clinicians in
have commenced advanced radiosurgery treatments using Varian's Calypso® 'GPS for the Body' real-time tumor tracking system. Doctors at the 'Champalimaud Center for the Unknown' (CCU) utilized the Calypso system to enhance precision during a radiosurgery treatment that included the world's first clinical use of the new commercially available Calypso lung Beacon® transponder.
The center has used this method to treat three patients with stage 1 non-small-cell lung cancer (NSCLC), according to Professor
, head of radiation oncology at CCU.
"Our experience so far is that tracking tumors with Calypso transponders may help make a significant difference in lung treatments," says Professor Greco. "In the past, we would have to apply a more generous treatment margin around the tumor and we would have had difficulty checking for or responding to movement caused by the patient coughing. Calypso allows us to monitor the treatment real-time and reduce the treatment margin, meaning less healthy tissue is treated."
"Calypso is a tracking and monitoring device that provides additional evidence that the dose is being delivered where it should be, which is even more important in higher dose treatments," Professor Greco added.
Calypso lung transponders¹ are implanted devices that are currently used in combination with Varian's TrueBeam™ medical linear accelerator at CCU to provide advanced stereotactic radiosurgery treatments. In November, the same hospital is scheduled to become the first in the world to commence treatments using Varian's new Edge™ dedicated radiosurgery system.
Calypso surface transponders that are fixed to the patient's skin are also utilized at CCU to track motion in thoracic and abdominal tumors being treated using high-dose stereotactic ablative body radiotherapy (SABR). "Real-time tracking of motion is vital if the tumor is close to a critical structure," says Professor Greco. "These surface transponders detect truly valuable information that can enhance precision and allow us to stop the treatment if the target moves beyond a certain threshold."